Protein tyrosine kinase regulation by ubiquitination: Critical roles of Cbl-family ubiquitin ligases

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1833, Issue 1, 2013, Pages 122-139

  Mohapatra, Bhopal ^a   Ahmad, Gulzar ^a   Nadeau, Scott ^a,b   Zutshi, Neha ^a   An, Wei ^a,b   Scheffe, Sarah ^a,b   Dong, Lin ^a,b   Feng, Dan ^a   Goetz, Benjamin ^a   Arya, Priyanka ^a,b   Bailey, Tameka A ^a   Palermo, Nicholas ^c   Borgstahl, Gloria E O ^a   Natarajan, Amarnath ^a   Raja, Srikumar M ^a   Naramura, Mayumi ^a,b   Band, Vimla ^a,b   Band, Hamid ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEBRASKA LINCOLN   (United States)

Author keywords

Animal model; Cbl; E3 ubiquitin ligase; Signal transduction; Tyrosine kinase binding domain; Ubiquitination

Indexed keywords

CBL PROTEIN; CELL SURFACE RECEPTOR; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEASOME; PROTEIN TYROSINE KINASE; TYROSINE KINASE RECEPTOR; UBIQUITIN; UBIQUITIN CONJUGATING ENZYME; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE E3;

ATYPICAL CHRONIC MYELOID LEUKEMIA; BIOCHEMISTRY; CHRONIC MYELOMONOCYTIC LEUKEMIA; CYTOLOGY; EMBRYOTOXICITY; ENDOCYTOSIS; ENDOSOME; ENZYME ACTIVATION; ENZYME DEGRADATION; ENZYME MODIFICATION; ENZYME REGULATION; GENE DELETION; GENE MUTATION; GENETIC CONSERVATION; HUMAN; JUVENILE MYELOMONOCYTIC LEUKEMIA; LYSOSOME; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; PROTEIN TARGETING; PROTEIN TRANSPORT; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; UBIQUITINATION;

AMINO ACID SEQUENCE; ANIMALS; HUMANS; MICE; MODELS, BIOLOGICAL; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-CBL; SIGNAL TRANSDUCTION; UBIQUITIN; UBIQUITINATION;

ANIMALIA; MAMMALIA; MUS;

EID: 84869112362     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2012.10.010     Document Type: Review

References (219)

1. Hunter T. Tyrosine phosphorylation: thirty years and counting. Curr. Opin. Cell Biol. 2009, 21:140-146.
2. Weiss A. The right team at the right time to go for a home run: tyrosine kinase activation by the TCR. Nat. Immunol. 2010, 11:101-104.
3. Ghoreschi K., Laurence A., O'Shea J.J. Janus kinases in immune cell signaling. Immunol. Rev. 2009, 228:273-287.
4. Hendriks W.J., Elson A., Harroch S., Stoker A.W. Protein tyrosine phosphatases: functional inferences from mouse models and human diseases. FEBS J. 2008, 275:816-830.
5. Julien S.G., Dube N., Hardy S., Tremblay M.L. Inside the human cancer tyrosine phosphatome. Nat. Rev. Cancer 2011, 11:35-49.
6. Carpenter G. The EGF receptor: a nexus for trafficking and signaling. Bioessays 2000, 22:697-707.
7. Waterman H., Yarden Y. Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases. FEBS Lett. 2001, 490:142-152.
8. Wells A., Welsh J.B., Lazar C.S., Wiley H.S., Gill G.N., Rosenfeld M.G. Ligand-induced transformation by a noninternalizing epidermal growth factor receptor. Science 1990, 247:962-964.
9. Hynes N.E., Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 2005, 5:341-354.
10. Harari D., Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 2000, 19:6102-6114.
11. McClintock J.L., Ceresa B.P. Transforming growth factor-{alpha} enhances corneal epithelial cell migration by promoting EGFR recycling. Invest. Ophthalmol. Vis. Sci. 2010, 51:3455-3461.
12. Ouyang X., Gulliford T., Huang G., Epstein R.J. Transforming growth factor-alpha short-circuits downregulation of the epidermal growth factor receptor. J. Cell. Physiol. 1999, 179:52-57.
13. Roepstorff K., Grandal M.V., Henriksen L., Knudsen S.L., Lerdrup M., Grovdal L., Willumsen B.M., van Deurs B. Differential effects of EGFR ligands on endocytic sorting of the receptor. Traffic 2009, 10:1115-1127.
14. Sigismund S., Argenzio E., Tosoni D., Cavallaro E., Polo S., Di Fiore P.P. Clathrin-mediated internalization is essential for sustained EGFR signaling but dispensable for degradation. Dev. Cell 2008, 15:209-219.
15. Di Fiore P.P., De Camilli P. Endocytosis and signaling. An inseparable partnership. Cell 2001, 106:1-4.
16. Barker P.A., Hussain N.K., McPherson P.S. Retrograde signaling by the neurotrophins follows a well-worn trk. Trends Neurosci. 2002, 25:379-381.
17. McPherson P.S., Kay B.K., Hussain N.K. Signaling on the endocytic pathway. Traffic 2001, 2:375-384.
18. Seto E.S., Bellen H.J., Lloyd T.E. When cell biology meets development: endocytic regulation of signaling pathways. Genes Dev. 2002, 16:1314-1336.
19. Burke P., Schooler K., Wiley H.S. Regulation of epidermal growth factor receptor signaling by endocytosis and intracellular trafficking. Mol. Biol. Cell 2001, 12:1897-1910.
20. Qui M.S., Green S.H. PC12 cell neuronal differentiation is associated with prolonged p21ras activity and consequent prolonged ERK activity. Neuron 1992, 9:705-717.
21. Pasic L., Eisinger-Mathason T.S., Velayudhan B.T., Moskaluk C.A., Brenin D.R., Macara I.G., Lannigan D.A. Sustained activation of the HER1-ERK1/2-RSK signaling pathway controls myoepithelial cell fate in human mammary tissue. Genes Dev. 2011, 25:1641-1653.
22. Vieira A.V., Lamaze C., Schmid S.L. Control of EGF receptor signaling by clathrin-mediated endocytosis. Science 1996, 274:2086-2089.
23. Teis D., Wunderlich W., Huber L.A. Localization of the MP1-MAPK scaffold complex to endosomes is mediated by p14 and required for signal transduction. Dev. Cell 2002, 3:803-814.
24. Wunderlich W., Fialka I., Teis D., Alpi A., Pfeifer A., Parton R.G., Lottspeich F., Huber L.A. A novel 14-kilodalton protein interacts with the mitogen-activated protein kinase scaffold mp1 on a late endosomal/lysosomal compartment. J. Cell Biol. 2001, 152:765-776.
25. Chiu V.K., Bivona T., Hach A., Sajous J.B., Silletti J., Wiener H., Johnson R.L., Cox A.D., Philips M.R. Ras signalling on the endoplasmic reticulum and the Golgi. Nat. Cell Biol. 2002, 4:343-350.
26. Bild A.H., Turkson J., Jove R. Cytoplasmic transport of Stat3 by receptor-mediated endocytosis. EMBO J. 2002, 21:3255-3263.
27. Panopoulou E., Gillooly D.J., Wrana J.L., Zerial M., Stenmark H., Murphy C., Fotsis T. Early endosomal regulation of Smad-dependent signaling in endothelial cells. J. Biol. Chem. 2002, 277:18046-18052.
28. Pierce K.L., Luttrell L.M., Lefkowitz R.J. New mechanisms in heptahelical receptor signaling to mitogen activated protein kinase cascades. Oncogene 2001, 20:1532-1539.
29. Pennock S., Wang Z. Stimulation of cell proliferation by endosomal epidermal growth factor receptor as revealed through two distinct phases of signaling. Mol. Cell. Biol. 2003, 23:5803-5815.
30. Wang Y., Pennock S., Chen X., Wang Z. Endosomal signaling of epidermal growth factor receptor stimulates signal transduction pathways leading to cell survival. Mol. Cell. Biol. 2002, 22:7279-7290.
31. Wiley H.S., Herbst J.J., Walsh B.J., Lauffenburger D.A., Rosenfeld M.G., Gill G.N. The role of tyrosine kinase activity in endocytosis, compartmentation, and down-regulation of the epidermal growth factor receptor. J. Biol. Chem. 1991, 266:11083-11094.
32. Deshaies R.J., Joazeiro C.A. RING domain E3 ubiquitin ligases. Annu. Rev. Biochem. 2009, 78:399-434.
33. Schulman B.A., Harper J.W. Ubiquitin-like protein activation by E1 enzymes: the apex for downstream signalling pathways. Nat. Rev. Mol. Cell Biol. 2009, 10:319-331.
34. Macgurn J.A., Hsu P.C., Emr S.D. Ubiquitin and membrane protein turnover: from cradle to grave. Annu. Rev. Biochem. 2012, 81:231-259.
35. Wegner C.S., Rodahl L.M., Stenmark H. ESCRT proteins and cell signalling. Traffic 2011, 12:1291-1297.
36. Henne W.M., Buchkovich N.J., Emr S.D. The ESCRT pathway. Dev. Cell 2011, 21:77-91.
37. Babst M. MVB vesicle formation: ESCRT-dependent, ESCRT-independent and everything in between. Curr. Opin. Cell Biol. 2011, 23:452-457.
38. Rusten T.E., Vaccari T., Stenmark H. Shaping development with ESCRTs. Nat. Cell Biol. 2011, 14:38-45.
39. Shields S.B., Piper R.C. How ubiquitin functions with ESCRTs. Traffic 2011, 12:1306-1317.
40. Mizuno E., Iura T., Mukai A., Yoshimori T., Kitamura N., Komada M. Regulation of epidermal growth factor receptor down-regulation by UBPY-mediated deubiquitination at endosomes. Mol. Biol. Cell 2005, 16:5163-5174.
41. Row P.E., Prior I.A., McCullough J., Clague M.J., Urbe S. The ubiquitin isopeptidase UBPY regulates endosomal ubiquitin dynamics and is essential for receptor down-regulation. J. Biol. Chem. 2006, 281:12618-12624.
42. Wright M.H., Berlin I., Nash P.D. Regulation of endocytic sorting by ESCRT-DUB-mediated deubiquitination. Cell Biochem. Biophys. 2011, 60:39-46.
43. McCullough J., Row P.E., Lorenzo O., Doherty M., Beynon R., Clague M.J., Urbe S. Activation of the endosome-associated ubiquitin isopeptidase AMSH by STAM, a component of the multivesicular body-sorting machinery. Curr. Biol. 2006, 16:160-165.
44. Ma Y.M., Boucrot E., Villen J., Affar el B., Gygi S.P., Gottlinger H.G., Kirchhausen T. Targeting of AMSH to endosomes is required for epidermal growth factor receptor degradation. J. Biol. Chem. 2007, 282:9805-9812.
45. Row P.E., Liu H., Hayes S., Welchman R., Charalabous P., Hofmann K., Clague M.J., Sanderson C.M., Urbe S. The MIT domain of UBPY constitutes a CHMP binding and endosomal localization signal required for efficient epidermal growth factor receptor degradation. J. Biol. Chem. 2007, 282:30929-30937.
46. Wu X., Yen L., Irwin L., Sweeney C., Carraway K.L. Stabilization of the E3 ubiquitin ligase Nrdp1 by the deubiquitinating enzyme USP8. Mol. Cell. Biol. 2004, 24:7748-7757.
47. Meenhuis A., Verwijmeren C., Roovers O., Touw I.P. The deubiquitinating enzyme DUB2A enhances CSF3 signalling by attenuating lysosomal routing of the CSF3 receptor. Biochem. J. 2011, 434:343-351.
48. Berlin I., Schwartz H., Nash P.D. Regulation of epidermal growth factor receptor ubiquitination and trafficking by the USP8.STAM complex. J. Biol. Chem. 2010, 285:34909-34921.
49. Z. Liu, S.M. Zanata, J. Kim, M.A. Peterson, D. Di Vizio, L.R. Chirieac, S. Pyne, M. Agostini, M.R. Freeman, M. Loda, The ubiquitin-specific protease USP2a prevents endocytosis-mediated EGFR degradation, Oncogene (in press) (Epub ahead of print, Jun 18 2012).
50. Pareja F., Ferraro D.A., Rubin C., Cohen-Dvashi H., Zhang F., Aulmann S., Ben-Chetrit N., Pines G., Navon R., Crosetto N., Kostler W., Carvalho S., Lavi S., Schmitt F., Dikic I., Yakhini Z., Sinn P., Mills G.B., Yarden Y. Deubiquitination of EGFR by Cezanne-1 contributes to cancer progression. Oncogene 2012, 31:4599-4608.
51. Harhaj E.W., Dixit V.M. Regulation of NF-kappaB by deubiquitinases. Immunol. Rev. 2012, 246:107-124.
52. Lu Z., Hunter T. Degradation of activated protein kinases by ubiquitination. Annu. Rev. Biochem. 2009, 78:435-475.
53. Mori S., Heldin C.H., Claesson-Welsh L. Ligand-induced polyubiquitination of the platelet-derived growth factor beta-receptor. J. Biol. Chem. 1992, 267:6429-6434.
54. Langdon W.Y., Hartley J.W., Klinken S.P., Ruscetti S.K., Morse H.C. v-cbl, an oncogene from a dual-recombinant murine retrovirus that induces early B-lineage lymphomas. Proc. Natl. Acad. Sci. U.S.A. 1989, 86:1168-1172.
55. Blake T.J., Heath K.G., Langdon W.Y. The truncation that generated the v-cbl oncogene reveals an ability for nuclear transport, DNA binding and acute transformation. EMBO J. 1993, 12:2017-2026.
56. Meng W., Sawasdikosol S., Burakoff S.J., Eck M.J. Structure of the amino-terminal domain of Cbl complexed to its binding site on ZAP-70 kinase. Nature 1999, 398:84-90.
57. Zheng N., Wang P., Jeffrey P.D., Pavletich N.P. Structure of a c-Cbl-UbcH7 complex: RING domain function in ubiquitin-protein ligases. Cell 2000, 102:533-539.
58. Ota S., Hazeki K., Rao N., Lupher M.L., Andoniou C.E., Druker B., Band H. The RING finger domain of Cbl is essential for negative regulation of the Syk tyrosine kinase. J. Biol. Chem. 2000, 275:414-422.
59. Lill N.L., Douillard P., Awwad R.A., Ota S., Lupher M.L., Miyake S., Meissner-Lula N., Hsu V.W., Band H. The evolutionarily conserved N-terminal region of Cbl is sufficient to enhance down-regulation of the epidermal growth factor receptor. J. Biol. Chem. 2000, 275:367-377.
60. Lupher M.L., Rao N., Eck M.J., Band H. The Cbl protooncoprotein: a negative regulator of immune receptor signal transduction. Immunol. Today 1999, 20:375-382.
61. Naramura M., Band V., Band H. Indispensable roles of mammalian Cbl family proteins as negative regulators of protein tyrosine kinase signaling: insights from in vivo models. Commun. Integr. Biol. 2011, 4:159-162.
62. Naramura M., Nadeau S., Mohapatra B., Ahmad G., Mukhopadhyay C., Sattler M., Raja S.M., Natarajan A., Band V., Band H. Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders. Oncotarget 2011, 2:245-250.
63. Duan L., Reddi A.L., Ghosh A., Dimri M., Band H. The Cbl family and other ubiquitin ligases: destructive forces in control of antigen receptor signaling. Immunity 2004, 21:7-17.
64. Thien C.B., Langdon W.Y. c-Cbl and Cbl-b ubiquitin ligases: substrate diversity and the negative regulation of signalling responses. Biochem. J. 2005, 391:153-166.
65. Lipkowitz S., Weissman A.M. RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis. Nat. Rev. Cancer 2011, 11:629-643.
66. Bartkiewicz M., Houghton A., Baron R. Leucine zipper-mediated homodimerization of the adaptor protein c-Cbl. A role in c-Cbl's tyrosine phosphorylation and its association with epidermal growth factor receptor. J. Biol. Chem. 1999, 274:30887-30895.
67. Davies G.C., Ettenberg S.A., Coats A.O., Mussante M., Ravichandran S., Collins J., Nau M.M., Lipkowitz S. Cbl-b interacts with ubiquitinated proteins; differential functions of the UBA domains of c-Cbl and Cbl-b. Oncogene 2004, 23:7104-7115.
68. Peschard P., Kozlov G., Lin T., Mirza I.A., Berghuis A.M., Lipkowitz S., Park M., Gehring K. Structural basis for ubiquitin-mediated dimerization and activation of the ubiquitin protein ligase Cbl-b. Mol. Cell 2007, 27:474-485.
69. Nau M.M., Lipkowitz S. Comparative genomic organization of the cbl genes. Gene 2003, 308:103-113.
70. Keane M.M., Ettenberg S.A., Nau M.M., Banerjee P., Cuello M., Penninger J., Lipkowitz S. Cbl-3: a new mammalian Cbl family protein. Oncogene 1999, 18:3365-3375.
71. Langenick J., Araki T., Yamada Y., Williams J.G. A Dictyostelium homologue of the metazoan Cbl proteins regulates STAT signalling. J. Cell Sci. 2008, 121:3524-3530.
72. Blake T.J., Shapiro M., Morse H.C., Langdon W.Y. The sequences of the human and mouse c-cbl proto-oncogenes show v-cbl was generated by a large truncation encompassing a proline-rich domain and a leucine zipper-like motif. Oncogene 1991, 6:653-657.
73. Andoniou C.E., Thien C.B., Langdon W.Y. Tumour induction by activated abl involves tyrosine phosphorylation of the product of the cbl oncogene. EMBO J. 1994, 13:4515-4523.
74. Donovan J.A., Wange R.L., Langdon W.Y., Samelson L.E. The protein product of the c-cbl protooncogene is the 120-kDa tyrosine-phosphorylated protein in Jurkat cells activated via the T cell antigen receptor. J. Biol. Chem. 1994, 269:22921-22924.
75. Reedquist K.A., Fukazawa T., Druker B., Panchamoorthy G., Shoelson S.E., Band H. Rapid T-cell receptor-mediated tyrosine phosphorylation of p120, an Fyn/Lck Src homology 3 domain-binding protein. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:4135-4139.
76. Fukazawa T., Reedquist K.A., Trub T., Soltoff S., Panchamoorthy G., Druker B., Cantley L., Shoelson S.E., Band H. The SH3 domain-binding T cell tyrosyl phosphoprotein p120. Demonstration of its identity with the c-cbl protooncogene product and in vivo complexes with Fyn, Grb2, and phosphatidylinositol 3-kinase. J. Biol. Chem. 1995, 270:19141-19150.
77. Rao N., Dodge I., Band H. The Cbl family of ubiquitin ligases: critical negative regulators of tyrosine kinase signaling in the immune system. J. Leukoc. Biol. 2002, 71:753-763.
78. Thien C.B., Langdon W.Y. Cbl: many adaptations to regulate protein tyrosine kinases. Nat. Rev. Mol. Cell Biol. 2001, 2:294-307.
79. Tsygankov A.Y., Teckchandani A.M., Feshchenko E.A., Swaminathan G. Beyond the RING: CBL proteins as multivalent adapters. Oncogene 2001, 20:6382-6402.
80. Fukazawa T., Miyake S., Band V., Band H. Tyrosine phosphorylation of Cbl upon epidermal growth factor (EGF) stimulation and its association with EGF receptor and downstream signaling proteins. J. Biol. Chem. 1996, 271:14554-14559.
81. Panchamoorthy G., Fukazawa T., Miyake S., Soltoff S., Reedquist K., Druker B., Shoelson S., Cantley L., Band H. p120cbl is a major substrate of tyrosine phosphorylation upon B cell antigen receptor stimulation and interacts in vivo with Fyn and Syk tyrosine kinases, Grb2 and Shc adaptors, and the p85 subunit of phosphatidylinositol 3-kinase. J. Biol. Chem. 1996, 271:3187-3194.
82. Bonita D.P., Miyake S., Lupher M.L., Langdon W.Y., Band H. Phosphotyrosine binding domain-dependent upregulation of the platelet-derived growth factor receptor alpha signaling cascade by transforming mutants of Cbl: implications for Cbl's function and oncogenicity. Mol. Cell. Biol. 1997, 17:4597-4610.
83. Meisner H., Conway B.R., Hartley D., Czech M.P. Interactions of Cbl with Grb2 and phosphatidylinositol 3'-kinase in activated Jurkat cells. Mol. Cell. Biol. 1995, 15:3571-3578.
84. Yoon C.H., Lee J., Jongeward G.D., Sternberg P.W. Similarity of sli-1, a regulator of vulval development in C. elegans, to the mammalian proto-oncogene c-cbl. Science 1995, 269:1102-1105.
85. Lupher M.L., Reedquist K.A., Miyake S., Langdon W.Y., Band H. A novel phosphotyrosine-binding domain in the N-terminal transforming region of Cbl interacts directly and selectively with ZAP-70 in T cells. J. Biol. Chem. 1996, 271:24063-24068.
86. Lupher M.L., Rao N., Lill N.L., Andoniou C.E., Miyake S., Clark E.A., Druker B., Band H. Cbl-mediated negative regulation of the Syk tyrosine kinase. A critical role for Cbl phosphotyrosine-binding domain binding to Syk phosphotyrosine 323. J. Biol. Chem. 1998, 273:35273-35281.
87. Lupher M.L., Songyang Z., Shoelson S.E., Cantley L.C., Band H. The Cbl phosphotyrosine-binding domain selects a D(N/D)XpY motif and binds to the Tyr292 negative regulatory phosphorylation site of ZAP-70. J. Biol. Chem. 1997, 272:33140-33144.
88. Miyake S., Mullane-Robinson K.P., Lill N.L., Douillard P., Band H. Cbl-mediated negative regulation of platelet-derived growth factor receptor-dependent cell proliferation. A critical role for Cbl tyrosine kinase-binding domain. J. Biol. Chem. 1999, 274:16619-16628.
89. Thien C.B., Langdon W.Y. Tyrosine kinase activity of the EGF receptor is enhanced by the expression of oncogenic 70Z-Cbl. Oncogene 1997, 15:2909-2919.
90. Miyake S., Lupher M.L., Druker B., Band H. The tyrosine kinase regulator Cbl enhances the ubiquitination and degradation of the platelet-derived growth factor receptor alpha. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:7927-7932.
91. Hicke L., Riezman H. Ubiquitination of a yeast plasma membrane receptor signals its ligand-stimulated endocytosis. Cell 1996, 84:277-287.
92. Terrell J., Shih S., Dunn R., Hicke L. A function for monoubiquitination in the internalization of a G protein-coupled receptor. Mol. Cell 1998, 1:193-202.
93. Abella J.V., Peschard P., Naujokas M.A., Lin T., Saucier C., Urbe S., Park M. Met/Hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation. Mol. Cell. Biol. 2005, 25:9632-9645.
94. Lee P.S., Wang Y., Dominguez M.G., Yeung Y.G., Murphy M.A., Bowtell D.D., Stanley E.R. The Cbl protooncoprotein stimulates CSF-1 receptor multiubiquitination and endocytosis, and attenuates macrophage proliferation. EMBO J. 1999, 18:3616-3628.
95. Peschard P., Fournier T.M., Lamorte L., Naujokas M.A., Band H., Langdon W.Y., Park M. Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol. Cell 2001, 8:995-1004.
96. Rao N., Ghosh A.K., Douillard P., Andoniou C.E., Zhou P., Band H. An essential role of ubiquitination in Cbl-mediated negative regulation of the Src-family kinase Fyn. Signal Transduct. 2002, 2:29-39.
97. Rao N., Ghosh A.K., Ota S., Zhou P., Reddi A.L., Hakezi K., Druker B.K., Wu J., Band H. The non-receptor tyrosine kinase Syk is a target of Cbl-mediated ubiquitylation upon B-cell receptor stimulation. EMBO J. 2001, 20:7085-7095.
98. Rao N., Miyake S., Reddi A.L., Douillard P., Ghosh A.K., Dodge I.L., Zhou P., Fernandes N.D., Band H. Negative regulation of Lck by Cbl ubiquitin ligase. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:3794-3799.
99. Rao N., Lupher M.L., Ota S., Reedquist K.A., Druker B.J., Band H. The linker phosphorylation site Tyr292 mediates the negative regulatory effect of Cbl on ZAP-70 in T cells. J. Immunol. 2000, 164:4616-4626.
100. Joazeiro C.A., Wing S.S., Huang H., Leverson J.D., Hunter T., Liu Y.C. The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. Science 1999, 286:309-312.
101. Levkowitz G., Waterman H., Ettenberg S.A., Katz M., Tsygankov A.Y., Alroy I., Lavi S., Iwai K., Reiss Y., Ciechanover A., Lipkowitz S., Yarden Y. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol. Cell 1999, 4:1029-1040.
102. Ettenberg S.A., Magnifico A., Cuello M., Nau M.M., Rubinstein Y.R., Yarden Y., Weissman A.M., Lipkowitz S. Cbl-b-dependent coordinated degradation of the epidermal growth factor receptor signaling complex. J. Biol. Chem. 2001, 276:27677-27684.
103. Kim M., Tezuka T., Tanaka K., Yamamoto T. Cbl-c suppresses v-Src-induced transformation through ubiquitin-dependent protein degradation. Oncogene 2004, 23:1645-1655.
104. Ryan P.E., Sivadasan-Nair N., Nau M.M., Nicholas S., Lipkowitz S. The N terminus of Cbl-c regulates ubiquitin ligase activity by modulating affinity for the ubiquitin-conjugating enzyme. J. Biol. Chem. 2010, 285:23687-23698.
105. Kales S.C., Ryan P.E., Lipkowitz S. Cbl exposes its RING finger. Nat. Struct. Mol. Biol. 2012, 19:131-133.
106. Ng C., Jackson R.A., Buschdorf J.P., Sun Q., Guy G.R., Sivaraman J. Structural basis for a novel intrapeptidyl H-bond and reverse binding of c-Cbl-TKB domain substrates. EMBO J. 2008, 27:804-816.
107. Penengo L., Rubin C., Yarden Y., Gaudino G. c-Cbl is a critical modulator of the Ron tyrosine kinase receptor. Oncogene 2003, 22:3669-3679.
108. Peschard P., Ishiyama N., Lin T., Lipkowitz S., Park M. A conserved DpYR motif in the juxtamembrane domain of the Met receptor family forms an atypical c-Cbl/Cbl-b tyrosine kinase binding domain binding site required for suppression of oncogenic activation. J. Biol. Chem. 2004, 279:29565-29571.
109. Hu J., Hubbard S.R. Structural characterization of a novel Cbl phosphotyrosine recognition motif in the APS family of adapter proteins. J. Biol. Chem. 2005, 280:18943-18949.
110. Masson K., Heiss E., Band H., Ronnstrand L. Direct binding of Cbl to Tyr568 and Tyr936 of the stem cell factor receptor/c-Kit is required for ligand-induced ubiquitination, internalization and degradation. Biochem. J. 2006, 399:59-67.
111. Wu G., Xu G., Schulman B.A., Jeffrey P.D., Harper J.W., Pavletich N.P. Structure of a beta-TrCP1-Skp1-beta-catenin complex: destruction motif binding and lysine specificity of the SCF(beta-TrCP1) ubiquitin ligase. Mol. Cell 2003, 11:1445-1456.
112. Thien C.B., Walker F., Langdon W.Y. RING finger mutations that abolish c-Cbl-directed polyubiquitination and downregulation of the EGF receptor are insufficient for cell transformation. Mol. Cell 2001, 7:355-365.
113. Kobashigawa Y., Tomitaka A., Kumeta H., Noda N.N., Yamaguchi M., Inagaki F. Autoinhibition and phosphorylation-induced activation mechanisms of human cancer and autoimmune disease-related E3 protein Cbl-b. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:20579-20584.
114. Dou H., Buetow L., Hock A., Sibbet G.J., Vousden K.H., Huang D.T. Structural basis for autoinhibition and phosphorylation-dependent activation of c-Cbl. Nat. Struct. Mol. Biol. 2012, 19:184-192.
115. Schmidt M.H., Furnari F.B., Cavenee W.K., Bogler O. Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:6505-6510.
116. Ghosh A.K., Reddi A.L., Rao N.L., Duan L., Band V., Band H. Biochemical basis for the requirement of kinase activity for Cbl-dependent ubiquitinylation and degradation of a target tyrosine kinase. J. Biol. Chem. 2004, 279:36132-36141.
117. Kassenbrock C.K., Anderson S.M. Regulation of ubiquitin protein ligase activity in c-Cbl by phosphorylation-induced conformational change and constitutive activation by tyrosine to glutamate point mutations. J. Biol. Chem. 2004, 279:28017-28027.
118. Rosenkranz S., Ikuno Y., Leong F.L., Klinghoffer R.A., Miyake S., Band H., Kazlauskas A. Src family kinases negatively regulate platelet-derived growth factor alpha receptor-dependent signaling and disease progression. J. Biol. Chem. 2000, 275:9620-9627.
119. Liu Y.C., Gu H. Cbl and Cbl-b in T-cell regulation. Trends Immunol. 2002, 23:140-143.
120. Miura-Shimura Y., Duan L., Rao N.L., Reddi A.L., Shimura H., Rottapel R., Druker B.J., Tsygankov A., Band V., Band H. Cbl-mediated ubiquitinylation and negative regulation of Vav. J. Biol. Chem. 2003, 278:38495-38504.
121. Duan L., Raja S.M., Chen G., Virmani S., Williams S.H., Clubb R.J., Mukhopadhyay C., Rainey M.A., Ying G., Dimri M., Chen J., Reddi A.L., Naramura M., Band V., Band H. Negative regulation of EGFR-Vav2 signaling axis by Cbl ubiquitin ligase controls EGF receptor-mediated epithelial cell adherens junction dynamics and cell migration. J. Biol. Chem. 2011, 286:620-633.
122. Zhang W., Shao Y., Fang D., Huang J., Jeon M.S., Liu Y.C. Negative regulation of T cell antigen receptor-mediated Crk-L-C3G signaling and cell adhesion by Cbl-b. J. Biol. Chem. 2003, 278:23978-23983.
123. d'Azzo A., Bongiovanni A., Nastasi T. E3 ubiquitin ligases as regulators of membrane protein trafficking and degradation. Traffic 2005, 6:429-441.
124. Haglund K., Sigismund S., Polo S., Szymkiewicz I., Di Fiore P.P., Dikic I. Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation. Nat. Cell Biol. 2003, 5:461-466.
125. Levkowitz G., Waterman H., Zamir E., Kam Z., Oved S., Langdon W.Y., Beguinot L., Geiger B., Yarden Y. c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev. 1998, 12:3663-3674.
126. Umebayashi K., Stenmark H., Yoshimori T. Ubc4/5 and c-Cbl continue to ubiquitinate EGF receptor after internalization to facilitate polyubiquitination and degradation. Mol. Biol. Cell 2008, 19:3454-3462.
127. Fasen K., Cerretti D.P., Huynh-Do U. Ligand binding induces Cbl-dependent EphB1 receptor degradation through the lysosomal pathway. Traffic 2008, 9:251-266.
128. Huang F., Kirkpatrick D., Jiang X., Gygi S., Sorkin A. Differential regulation of EGF receptor internalization and degradation by multiubiquitination within the kinase domain. Mol. Cell 2006, 21:737-748.
129. Longva K.E., Blystad F.D., Stang E., Larsen A.M., Johannessen L.E., Madshus I.H. Ubiquitination and proteasomal activity is required for transport of the EGF receptor to inner membranes of multivesicular bodies. J. Cell Biol. 2002, 156:843-854.
130. Huang C. Roles of E3 ubiquitin ligases in cell adhesion and migration. Cell Adh. Migr. 2010, 4:10-18.
131. Ryan P.E., Davies G.C., Nau M.M., Lipkowitz S. Regulating the regulator: negative regulation of Cbl ubiquitin ligases. Trends Biochem. Sci. 2006, 31:79-88.
132. Reddi Alagarsamy L., Duan Lei, Rainey Mark A., Ortega-Cava Cesar, Clubb Robert, Chung Byung Min, Dimri Manjari, Tu Chun, George Manju, Raja Srikumar, Naramura Mayumi Cbl-family E3 ubiquitin ligases as regulators of non-receptor tyrosine kinases. Cbl Proteins 2008, 53-74. Nova Science Publishers. A. Tsygankov (Ed.).
133. Soubeyran P., Kowanetz K., Szymkiewicz I., Langdon W.Y., Dikic I. Cbl-CIN85-endophilin complex mediates ligand-induced downregulation of EGF receptors. Nature 2002, 416:183-187.
134. Petrelli A., Gilestro G.F., Lanzardo S., Comoglio P.M., Migone N., Giordano S. The endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation of c-Met. Nature 2002, 416:187-190.
135. Duan L., Miura Y., Dimri M., Majumder B., Dodge I.L., Reddi A.L., Ghosh A., Fernandes N., Zhou P., Mullane-Robinson K., Rao N., Donoghue S., Rogers R.A., Bowtell D., Naramura M., Gu H., Band V., Band H. Cbl-mediated ubiquitinylation is required for lysosomal sorting of epidermal growth factor receptor but is dispensable for endocytosis. J. Biol. Chem. 2003, 278:28950-28960.
136. Khan E.M., Heidinger J.M., Levy M., Lisanti M.P., Ravid T., Goldkorn T. Epidermal growth factor receptor exposed to oxidative stress undergoes Src- and caveolin-1-dependent perinuclear trafficking. J. Biol. Chem. 2006, 281:14486-14493.
137. Huang F., Goh L.K., Sorkin A. EGF receptor ubiquitination is not necessary for its internalization. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:16904-16909.
138. Goh L.K., Huang F., Kim W., Gygi S., Sorkin A. Multiple mechanisms collectively regulate clathrin-mediated endocytosis of the epidermal growth factor receptor. J. Cell Biol. 2010, 189:871-883.
139. Swaminathan G., Tsygankov A.Y. The Cbl family proteins: ring leaders in regulation of cell signaling. J. Cell. Physiol. 2006, 209:21-43.
140. Miura A., Sajan M.P., Standaert M.L., Bandyopadhyay G., Franklin D.M., Lea-Currie R., Farese R.V. Cbl PYXXM motifs activate the P85 subunit of phosphatidylinositol 3-kinase, Crk, atypical protein kinase C, and glucose transport during thiazolidinedione action in 3T3/L1 and human adipocytes. Biochemistry 2003, 42:14335-14341.
141. Standaert M.L., Sajan M.P., Miura A., Bandyopadhyay G., Farese R.V. Requirements for pYXXM motifs in Cbl for binding to the p85 subunit of phosphatidylinositol 3-kinase and Crk, and activation of atypical protein kinase C and glucose transport during insulin action in 3T3/L1 adipocytes. Biochemistry 2004, 43:15494-15502.
142. Goh E.L., Zhu T., Leong W.Y., Lobie P.E. c-Cbl is a negative regulator of GH-stimulated STAT5-mediated transcription. Endocrinology 2002, 143:3590-3603.
143. Wang L., Rudert W.A., Loutaev I., Roginskaya V., Corey S.J. Repression of c-Cbl leads to enhanced G-CSF Jak-STAT signaling without increased cell proliferation. Oncogene 2002, 21:5346-5355.
144. Timpson P., Lynch D.K., Schramek D., Walker F., Daly R.J. Cortactin overexpression inhibits ligand-induced down-regulation of the epidermal growth factor receptor. Cancer Res. 2005, 65:3273-3280.
145. Fong C.W., Leong H.F., Wong E.S., Lim J., Yusoff P., Guy G.R. Tyrosine phosphorylation of Sprouty2 enhances its interaction with c-Cbl and is crucial for its function. J. Biol. Chem. 2003, 278:33456-33464.
146. Wong E.S., Fong C.W., Lim J., Yusoff P., Low B.C., Langdon W.Y., Guy G.R. Sprouty2 attenuates epidermal growth factor receptor ubiquitylation and endocytosis, and consequently enhances Ras/ERK signalling. EMBO J. 2002, 21:4796-4808.
147. Wong E.S., Guy G.R. Regulator of epidermal growth factor signaling: Sprouty. Methods Mol. Biol. 2006, 327:61-83.
148. Wiedemann A., Muller S., Favier B., Penna D., Guiraud M., Delmas C., Champagne E., Valitutti S. T-cell activation is accompanied by an ubiquitination process occurring at the immunological synapse. Immunol. Lett. 2005, 98:57-61.
149. Jeon M.S., Atfield A., Venuprasad K., Krawczyk C., Sarao R., Elly C., Yang C., Arya S., Bachmaier K., Su L., Bouchard D., Jones R., Gronski M., Ohashi P., Wada T., Bloom D., Fathman C.G., Liu Y.C., Penninger J.M. Essential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction. Immunity 2004, 21:167-177.
150. Naramura M., Jang I.K., Kole H., Huang F., Haines D., Gu H. c-Cbl and Cbl-b regulate T cell responsiveness by promoting ligand-induced TCR down-modulation. Nat. Immunol. 2002, 3:1192-1199.
151. Rathinam C., Thien C.B., Langdon W.Y., Gu H., Flavell R.A. The E3 ubiquitin ligase c-Cbl restricts development and functions of hematopoietic stem cells. Genes Dev. 2008, 22:992-997.
152. Rathinam C., Thien C.B., Flavell R.A., Langdon W.Y. Myeloid leukemia development in c-Cbl RING finger mutant mice is dependent on FLT3 signaling. Cancer Cell 2010, 18:341-352.
153. Naramura M., Nandwani N., Gu H., Band V., Band H. Rapidly fatal myeloproliferative disorders in mice with deletion of Casitas B-cell lymphoma (Cbl) and Cbl-b in hematopoietic stem cells. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:16274-16279.
154. Ledda F., Paratcha G. Negative regulation of receptor tyrosine kinase (RTK) signaling: a developing field. Biomark. Insights 2007, 2:45-58.
155. Segatto O., Anastasi S., Alema S. Regulation of epidermal growth factor receptor signalling by inducible feedback inhibitors. J. Cell Sci. 2011, 124:1785-1793.
156. Ahmed A.U., Schmidt R.L., Park C.H., Reed N.R., Hesse S.E., Thomas C.F., Molina J.R., Deschamps C., Yang P., Aubry M.C., Tang A.H. Effect of disrupting seven-in-absentia homolog 2 function on lung cancer cell growth. J. Natl. Cancer Inst. 2008, 100:1606-1629.
157. Gur G., Rubin C., Katz M., Amit I., Citri A., Nilsson J., Amariglio N., Henriksson R., Rechavi G., Hedman H., Wides R., Yarden Y. LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J. 2004, 23:3270-3281.
158. Zhang X., Pickin K.A., Bose R., Jura N., Cole P.A., Kuriyan J. Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. Nature 2007, 450:741-744.
159. Frosi Y., Anastasi S., Ballaro C., Varsano G., Castellani L., Maspero E., Polo S., Alema S., Segatto O. A two-tiered mechanism of EGFR inhibition by RALT/MIG6 via kinase suppression and receptor degradation. J. Cell Biol. 2010, 189:557-571.
160. Schmid E.M., McMahon H.T. Integrating molecular and network biology to decode endocytosis. Nature 2007, 448:883-888.
161. Nicholson S.E., Metcalf D., Sprigg N.S., Columbus R., Walker F., Silva A., Cary D., Willson T.A., Zhang J.G., Hilton D.J., Alexander W.S., Nicola N.A. Suppressor of cytokine signaling (SOCS)-5 is a potential negative regulator of epidermal growth factor signaling. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:2328-2333.
162. Kario E., Marmor M.D., Adamsky K., Citri A., Amit I., Amariglio N., Rechavi G., Yarden Y. Suppressors of cytokine signaling 4 and 5 regulate epidermal growth factor receptor signaling. J. Biol. Chem. 2005, 280:7038-7048.
163. Tanaka Y., Tanaka N., Saeki Y., Tanaka K., Murakami M., Hirano T., Ishii N., Sugamura K. c-Cbl-dependent monoubiquitination and lysosomal degradation of gp130. Mol. Cell. Biol. 2008, 28:4805-4818.
164. Tarcic G., Boguslavsky S.K., Wakim J., Kiuchi T., Liu A., Reinitz F., Nathanson D., Takahashi T., Mischel P.S., Ng T., Yarden Y. An unbiased screen identifies DEP-1 tumor suppressor as a phosphatase controlling EGFR endocytosis. Curr. Biol. 2009, 19:1788-1798.
165. Guy G.R., Jackson R.A., Yusoff P., Chow S.Y. Sprouty proteins: modified modulators, matchmakers or missing links?. J. Endocrinol. 2009, 203:191-202.
166. Hanafusa H., Torii S., Yasunaga T., Nishida E. Sprouty1 and Sprouty2 provide a control mechanism for the Ras/MAPK signalling pathway. Nat. Cell Biol. 2002, 4:850-858.
167. Sasaki A., Taketomi T., Kato R., Saeki K., Nonami A., Sasaki M., Kuriyama M., Saito N., Shibuya M., Yoshimura A. Mammalian Sprouty4 suppresses Ras-independent ERK activation by binding to Raf1. Nat. Cell Biol. 2003, 5:427-432.
168. Wong E.S., Lim J., Low B.C., Chen Q., Guy G.R. Evidence for direct interaction between Sprouty and Cbl. J. Biol. Chem. 2001, 276:5866-5875.
169. Hall A.B., Jura N., DaSilva J., Jang Y.J., Gong D., Bar-Sagi D. hSpry2 is targeted to the ubiquitin-dependent proteasome pathway by c-Cbl. Curr. Biol. 2003, 13:308-314.
170. Rubin C., Litvak V., Medvedovsky H., Zwang Y., Lev S., Yarden Y. Sprouty fine-tunes EGF signaling through interlinked positive and negative feedback loops. Curr. Biol. 2003, 13:297-307.
171. Egan J.E., Hall A.B., Yatsula B.A., Bar-Sagi D. The bimodal regulation of epidermal growth factor signaling by human Sprouty proteins. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:6041-6046.
172. Choi H., Cho S.Y., Schwartz R.H., Choi K. Dual effects of Sprouty1 on TCR signaling depending on the differentiation state of the T cell. J. Immunol. 2006, 176:6034-6045.
173. Meisner H., Daga A., Buxton J., Fernandez B., Chawla A., Banerjee U., Czech M.P. Interactions of Drosophila Cbl with epidermal growth factor receptors and role of Cbl in R7 photoreceptor cell development. Mol. Cell. Biol. 1997, 17:2217-2225.
174. Pai L.M., Barcelo G., Schupbach T. D-cbl, a negative regulator of the Egfr pathway, is required for dorsoventral patterning in Drosophila oogenesis. Cell 2000, 103:51-61.
175. Nowak M., Machate A., Yu S.R., Gupta M., Brand M. Interpretation of the FGF8 morphogen gradient is regulated by endocytic trafficking. Nat. Cell Biol. 2011, 13:153-158.
176. Murphy M.A., Schnall R.G., Venter D.J., Barnett L., Bertoncello I., Thien C.B., Langdon W.Y., Bowtell D.D. Tissue hyperplasia and enhanced T-cell signalling via ZAP-70 in c-Cbl-deficient mice. Mol. Cell. Biol. 1998, 18:4872-4882.
177. Naramura M., Kole H.K., Hu R.J., Gu H. Altered thymic positive selection and intracellular signals in Cbl-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:15547-15552.
178. El Chami N., Ikhlef F., Kaszas K., Yakoub S., Tabone E., Siddeek B., Cunha S., Beaudoin C., Morel L., Benahmed M., Regnier D.C. Androgen-dependent apoptosis in male germ cells is regulated through the proto-oncoprotein Cbl. J. Cell Biol. 2005, 171:651-661.
179. Molero J.C., Jensen T.E., Withers P.C., Couzens M., Herzog H., Thien C.B., Langdon W.Y., Walder K., Murphy M.A., Bowtell D.D., James D.E., Cooney G.J. c-Cbl-deficient mice have reduced adiposity, higher energy expenditure, and improved peripheral insulin action. J. Clin. Invest. 2004, 114:1326-1333.
180. Bachmaier K., Krawczyk C., Kozieradzki I., Kong Y.Y., Sasaki T., Oliveira-dos-Santos A., Mariathasan S., Bouchard D., Wakeham A., Itie A., Le J., Ohashi P.S., Sarosi I., Nishina H., Lipkowitz S., Penninger J.M. Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature 2000, 403:211-216.
181. Chiang Y.J., Kole H.K., Brown K., Naramura M., Fukuhara S., Hu R.J., Jang I.K., Gutkind J.S., Shevach E., Gu H. Cbl-b regulates the CD28 dependence of T-cell activation. Nature 2000, 403:216-220.
182. Nakao R., Hirasaka K., Goto J., Ishidoh K., Yamada C., Ohno A., Okumura Y., Nonaka I., Yasutomo K., Baldwin K.M., Kominami E., Higashibata A., Nagano K., Tanaka K., Yasui N., Mills E.M., Takeda S., Nikawa T. Ubiquitin ligase Cbl-b is a negative regulator for insulin-like growth factor 1 signaling during muscle atrophy caused by unloading. Mol. Cell. Biol. 2009, 29:4798-4811.
183. Griffiths E.K., Sanchez O., Mill P., Krawczyk C., Hojilla C.V., Rubin E., Nau M.M., Khokha R., Lipkowitz S., Hui C.C., Penninger J.M. Cbl-3-deficient mice exhibit normal epithelial development. Mol. Cell. Biol. 2003, 23:7708-7718.
184. Langdon W.Y., Hyland C.D., Grumont R.J., Morse H.C. The c-cbl proto-oncogene is preferentially expressed in thymus and testis tissue and encodes a nuclear protein. J. Virol. 1989, 63:5420-5424.
185. Kitaura Y., Jang I.K., Wang Y., Han Y.C., Inazu T., Cadera E.J., Schlissel M., Hardy R.R., Gu H. Control of the B cell-intrinsic tolerance programs by ubiquitin ligases Cbl and Cbl-b. Immunity 2007, 26:567-578.
186. Sargin B., Choudhary C., Crosetto N., Schmidt M.H., Grundler R., Rensinghoff M., Thiessen C., Tickenbrock L., Schwable J., Brandts C., August B., Koschmieder S., Bandi S.R., Duyster J., Berdel W.E., Muller-Tidow C., Dikic I., Serve H. Flt3-dependent transformation by inactivating c-Cbl mutations in AML. Blood 2007, 110:1004-1012.
187. Caligiuri M.A., Briesewitz R., Yu J., Wang L., Wei M., Arnoczky K.J., Marburger T.B., Wen J., Perrotti D., Bloomfield C.D., Whitman S.P. Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia. Blood 2007, 110:1022-1024.
188. Makishima H., Cazzolli H., Szpurka H., Dunbar A., Tiu R., Huh J., Muramatsu H., O'Keefe C., Hsi E., Paquette R.L., Kojima S., List A.F., Sekeres M.A., McDevitt M.A., Maciejewski J.P. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J. Clin. Oncol. 2009, 27:6109-6116.
189. Brecqueville M., Rey J., Bertucci F., Coppin E., Finetti P., Carbuccia N., Cervera N., Gelsi-Boyer V., Arnoulet C., Gisserot O., Verrot D., Slama B., Vey N., Mozziconacci M.J., Birnbaum D., Murati A. Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. Genes Chromosomes Cancer 2012, 51:743-755.
190. Kao H.W., Sanada M., Liang D.C., Lai C.L., Lee E.H., Kuo M.C., Lin T.L., Shih Y.S., Wu J.H., Huang C.F., Ogawa S., Shih L.Y. A high occurrence of acquisition and/or expansion of C-CBL mutant clones in the progression of high-risk myelodysplastic syndrome to acute myeloid leukemia. Neoplasia 2011, 13:1035-1042.
191. Nicholson L., Knight T., Matheson E., Minto L., Case M., Sanichar M., Bomken S., Vormoor J., Hall A., Irving J. Casitas B lymphoma mutations in childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer 2012, 51:250-256.
192. Saito Y., Aoki Y., Muramatsu H., Makishima H., Maciejewski J.P., Imaizumi M., Rikiishi T., Sasahara Y., Kure S., Niihori T., Tsuchiya S., Kojima S., Matsubara Y. Casitas B-cell lymphoma mutation in childhood T-cell acute lymphoblastic leukemia. Leuk. Res. 2012, 36:1009-1015.
193. Schnittger S., Bacher U., Alpermann T., Reiter A., Ulke M., Dicker F., Eder C., Kohlmann A., Grossmann V., Kowarsch A., Kern W., Haferlach C., Haferlach T. Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myeloproliferative/myelodysplastic disorders: an analysis of 636 cases. Haematologica 2012.
194. Shiba N., Kato M., Park M.J., Sanada M., Ito E., Fukushima K., Sako M., Arakawa H., Ogawa S., Hayashi Y. CBL mutations in juvenile myelomonocytic leukemia and pediatric myelodysplastic syndrome. Leukemia 2010, 24:1090-1092.
195. Sanada M., Suzuki T., Shih L.Y., Otsu M., Kato M., Yamazaki S., Tamura A., Honda H., Sakata-Yanagimoto M., Kumano K., Oda H., Yamagata T., Takita J., Gotoh N., Nakazaki K., Kawamata N., Onodera M., Nobuyoshi M., Hayashi Y., Harada H., Kurokawa M., Chiba S., Mori H., Ozawa K., Omine M., Hirai H., Nakauchi H., Koeffler H.P., Ogawa S. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature 2009, 460:904-908.
196. Grand F.H., Hidalgo-Curtis C.E., Ernst T., Zoi K., Zoi C., McGuire C., Kreil S., Jones A., Score J., Metzgeroth G., Oscier D., Hall A., Brandts C., Serve H., Reiter A., Chase A.J., Cross N.C. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 2009, 113:6182-6192.
197. Bandi S.R., Brandts C., Rensinghoff M., Grundler R., Tickenbrock L., Kohler G., Duyster J., Berdel W.E., Muller-Tidow C., Serve H., Sargin B. Study Alliance Leukemias, E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease. Blood 2009, 114:4197-4208.
198. Liu X., Sabnis H., Bunting K.D., Qu C.K. Molecular targets for the treatment of juvenile myelomonocytic leukemia. Adv. Hematol. 2012, 2012:308252.
199. Mao J.H., Sun X.Y., Liu J.X., Zhang Q.Y., Liu P., Huang Q.H., Li K.K., Chen Q., Chen Z., Chen S.J. As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:21683-21688.
200. Makishima H., Sugimoto Y., Szpurka H., Clemente M.J., Ng K.P., Muramatsu H., O'Keefe C., Saunthararajah Y., Maciejewski J.P. CBL mutation-related patterns of phosphorylation and sensitivity to tyrosine kinase inhibitors. Leukemia 2012, 26:1547-1554.
201. Loh M.L. Childhood myelodysplastic syndrome: focus on the approach to diagnosis and treatment of juvenile myelomonocytic leukemia. Hematol. Am. Soc. Hematol. Educ. Program. 2010, 2010:357-362.
202. Tan Y.H., Krishnaswamy S., Nandi S., Kanteti R., Vora S., Onel K., Hasina R., Lo F.Y., El-Hashani E., Cervantes G., Robinson M., Hsu H.S., Kales S.C., Lipkowitz S., Karrison T., Sattler M., Vokes E.E., Wang Y.C., Salgia R. CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases. PLoS One 2010, 5:e8972.
203. Li Z., Dong T., Proschel C., Noble M. Chemically diverse toxicants converge on Fyn and c-Cbl to disrupt precursor cell function. PLoS Biol. 2007, 5:e35.
204. Ferron S.R., Pozo N., Laguna A., Aranda S., Porlan E., Moreno M., Fillat C., de la Luna S., Sanchez P., Arbones M.L., Farinas I. Regulated segregation of kinase Dyrk1A during asymmetric neural stem cell division is critical for EGFR-mediated biased signaling. Cell Stem Cell 2010, 7:367-379.
205. Doniz-Padilla L., Martinez-Jimenez V., Nino-Moreno P., Abud-Mendoza C., Hernandez-Castro B., Gonzalez-Amaro R., Layseca-Espinosa E., Baranda-Candido L. Expression and function of Cbl-b in T cells from patients with systemic lupus erythematosus, and detection of the 2126 A/G Cblb gene polymorphism in the Mexican mestizo population. Lupus 2011, 20:628-635.
206. Yokoi N., Komeda K., Wang H.Y., Yano H., Kitada K., Saitoh Y., Seino Y., Yasuda K., Serikawa T., Seino S. Cblb is a major susceptibility gene for rat type 1 diabetes mellitus. Nat. Genet. 2002, 31:391-394.
207. Yokoi N., Hayashi C., Fujiwara Y., Wang H.Y., Seino S. Genetic reconstitution of autoimmune type 1 diabetes with two major susceptibility genes in the rat. Diabetes 2007, 56:506-512.
208. Singh A.J., Meyer R.D., Navruzbekov G., Shelke R., Duan L., Band H., Leeman S.E., Rahimi N. A critical role for the E3-ligase activity of c-Cbl in VEGFR-2-mediated PLCgamma1 activation and angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:5413-5418.
209. Sanjay A., Houghton A., Neff L., DiDomenico E., Bardelay C., Antoine E., Levy J., Gailit J., Bowtell D., Horne W.C., Baron R. Cbl associates with Pyk2 and Src to regulate Src kinase activity, alpha(v)beta(3) integrin-mediated signaling, cell adhesion, and osteoclast motility. J. Cell Biol. 2001, 152:181-195.
210. Wilhelmsen K., Burkhalter S., van der Geer P. C-Cbl binds the CSF-1 receptor at tyrosine 973, a novel phosphorylation site in the receptor's carboxy-terminus. Oncogene 2002, 21:1079-1089.
211. Jekely G., Sung H.H., Luque C.M., Rorth P. Regulators of endocytosis maintain localized receptor tyrosine kinase signaling in guided migration. Dev. Cell 2005, 9:197-207.
212. Wang Y., Werz C., Xu D., Chen Z., Li Y., Hafen E., Bergmann A. Drosophila cbl is essential for control of cell death and cell differentiation during eye development. PLoS One 2008, 3:e1447.
213. Qiao G., Li Z., Molinero L., Alegre M.L., Ying H., Sun Z., Penninger J.M., Zhang J. T-cell receptor-induced NF-kappaB activation is negatively regulated by E3 ubiquitin ligase Cbl-b. Mol. Cell. Biol. 2008, 28:2470-2480.
214. Hirasaka K., Kohno S., Goto J., Furochi H., Mawatari K., Harada N., Hosaka T., Nakaya Y., Ishidoh K., Obata T., Ebina Y., Gu H., Takeda S., Kishi K., Nikawa T. Deficiency of Cbl-b gene enhances infiltration and activation of macrophages in adipose tissue and causes peripheral insulin resistance in mice. Diabetes 2007, 56:2511-2522.
215. Fiore F., Estebe B., Gibier P., Orsoni J.C., Courbard J.R., Chodosh L.A., Birnbaum D., Delapeyriere O. Abnormal mammary gland development in MMTV-CBLC transgenic mouse. In Vivo 2009, 23:225-228.
216. Thien C.B., Scaife R.M., Papadimitriou J.M., Murphy M.A., Bowtell D.D., Langdon W.Y. A mouse with a loss-of-function mutation in the c-Cbl TKB domain shows perturbed thymocyte signaling without enhancing the activity of the ZAP-70 tyrosine kinase. J. Exp. Med. 2003, 197:503-513.
217. Thien C.B., Blystad F.D., Zhan Y., Lew A.M., Voigt V., Andoniou C.E., Langdon W.Y. Loss of c-Cbl RING finger function results in high-intensity TCR signaling and thymic deletion. EMBO J. 2005, 24:3807-3819.
218. Adapala N.S., Barbe M.F., Langdon W.Y., Nakamura M.C., Tsygankov A.Y., Sanjay A. The loss of Cbl-phosphatidylinositol 3-kinase interaction perturbs RANKL-mediated signaling, inhibiting bone resorption and promoting osteoclast survival. J. Biol. Chem. 2010, 285:36745-36758.
219. Oksvold M.P., Dagger S.A., Thien C.B., Langdon W.Y. The Cbl-b RING finger domain has a limited role in regulating inflammatory cytokine production by IgE-activated mast cells. Mol. Immunol. 2008, 45:925-936.